Mitsugu Yamamoto

The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC)

Nobumoto Tomioka, Manabu Azuma, Mayuko Ikarashi et al. · Breast Cancer · 2017 · 105 citations

Breast Oncology, Cancer Immunosurveillance, Death Ligand 1 +11

Prognostic significance of pathologic complete response and Ki67 expression after neoadjuvant chemotherapy in breast cancer

Tatsuya Yoshioka, Mitsuchika Hosoda, Mitsugu Yamamoto et al. · Breast Cancer · 2013 · 103 citations

Breast Oncology, Medicine, Pathology +7

p53 accumulation is a strong predictor of recurrence in estrogen receptor‐positive breast cancer patients treated with aromatase inhibitors

Mitsugu Yamamoto, Mitsuchika Hosoda, Kiichiroh Nakano et al. · Cancer Science · 2013 · 76 citations · Full text

Endocrine Oncology, Breast Oncology, Medicine +15

Prognostic significance of pre-treatment neutrophil: lymphocyte ratio in Japanese patients with breast cancer.

Kiichiroh Nakano, Mitsuchika Hosoda, Mitsugu Yamamoto et al. · PubMed · 2014 · 47 citations

Differential expression of progesterone receptor, FOXA1, GATA3, and p53 between pre- and postmenopausal women with estrogen receptor-positive breast cancer

Mitsuchika Hosoda, Mitsugu Yamamoto, Kiichiroh Nakano et al. · Breast Cancer Research and Treatment · 2014 · 45 citations

Breast Oncology, Progesterone Receptor, Differential Expression +12